Dr. Goli Samimi received her Ph.D. in Biomedical Sciences from the University of California, San Diego, focusing on molecular mechanisms in ovarian cancer that conferred resistance to platinum-based chemotherapy. She then joined the Cancer Prevention Fellowship Program at the National Cancer Institute (NCI), focusing on molecular profiling of the tumor microenvironment in high-grade serous ovarian cancer. As part of the fellowship, she completed her Master of Public Health degree at Harvard School of Public Health. In 2011, Dr. Samimi joined the Garvan Institute of Medical Research in Sydney, Australia as Head of the Ovarian Cancer Research Group. Her lab focused on methylation in circulating DNA as a test for early detection of ovarian cancer, and the evaluation of a monoclonal antibody as a novel targeted therapeutic in high-grade serous ovarian cancer.
Dr. Samimi currently serves as a Program Director in the Breast and Gynecologic Cancer Research Group, managing the Ovarian Cancer Prevention portfolio and scientific monitoring of early phase ovarian cancer clinical trials within the NCI Division of Cancer Prevention Early Phase Prevention Consortia. Dr. Samimi’s research interests include molecular mechanisms of ovarian cancer etiology, circulating DNA as a biomarker of ovarian cancer, and improving identification of BRCA1/2 mutation carriers.